$3.04T
Total marketcap
$84.16B
Total volume
BTC 57.45%     ETH 11.68%
Dominance

ProPhase Labs PRPH Stock

$0.61   -10.480345%
Add to favorites
Market Cap
$2.58M
LOW - HIGH [24H]
$0.57 - $0.63
VOLUME [24H]
$968.29K
P/E Ratio
0
Earnings per share
-$19.80
Price   Prediction

ProPhase Labs Price Chart

Sorry, that's all we've gotfor now...

ProPhase Labs PRPH Financial and Trading Overview

ProPhase Labs stock price 0.62 USD
Previous Close 0.37 USD
Open 0.37 USD
Bid 0 USD x 0
Ask 0 USD x 0
Day's Range 0.35 - 0.39 USD
52 Week Range 0.22 - 3.37 USD
Volume 739.75K USD
Avg. Volume 2.21M USD
Market Cap 15.18M USD
Beta (5Y Monthly) -0.415
PE Ratio (TTM) N/A
EPS (TTM) -19.8 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date May 24, 2022
1y Target Est 13.8 USD

PRPH Valuation Measures

Enterprise Value 30.17M USD
Trailing P/E N/A
Forward P/E 0.7610417
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 2.596236
Price/Book (mrq) 1.0035714
Enterprise Value/Revenue 5.162
Enterprise Value/EBITDA -1.055

Trading Information

ProPhase Labs Stock Price History

Beta (5Y Monthly) -0.415
52-Week Change -88.10%
S&P500 52-Week Change 13.16%
52 Week High 3.37 USD
52 Week Low 0.22 USD
50-Day Moving Average 0.36 USD
200-Day Moving Average 0.73 USD

PRPH Share Statistics

Avg. Volume (3 month) 2.21M USD
Avg. Daily Volume (10-Days) 596.67K USD
Shares Outstanding 41.54M
Float 38.22M
Short Ratio 0.09
% Held by Insiders 7.99%
% Held by Institutions 12.14%
Shares Short 156.14K
Short % of Float 0.41%
Short % of Shares Outstanding 0.38%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2024
Most Recent Quarter (mrq) March 31, 2025
Next Fiscal Year End December 31, 2025

Profitability

Profit Margin 0%
Operating Margin (ttm) -255.97%
Gross Margin 7.45%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -30.91%
Return on Equity (ttm) -162.30%

Income Statement

Revenue (ttm) 5.85M USD
Revenue Per Share (ttm) 0.24 USD
Quarterly Revenue Growth (yoy) -39.30%
Gross Profit (ttm) 436K USD
EBITDA -28597000 USD
Net Income Avi to Common (ttm) -48679000 USD
Diluted EPS (ttm) -2.23
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 88K USD
Total Cash Per Share (mrq) 0.002 USD
Total Debt (mrq) 14.01M USD
Total Debt/Equity (mrq) 92.65 USD
Current Ratio (mrq) 1.03
Book Value Per Share (mrq) 0.364

Cash Flow Statement

Operating Cash Flow (ttm) -15779000 USD
Levered Free Cash Flow (ttm) 5.61M USD

Profile of ProPhase Labs

Country United States
State NY
City Garden City
Address 711 Stewart Avenue
ZIP 11530
Phone 215 345 0919
Website https://www.prophaselabs.com
Industry Diagnostics & Research
Sector(s) Healthcare
Full Time Employees 96

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Q&A For ProPhase Labs Stock

What is a current PRPH stock price?

ProPhase Labs PRPH stock price today per share is 0.62 USD.

How to purchase ProPhase Labs stock?

You can buy PRPH shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for ProPhase Labs?

The stock symbol or ticker of ProPhase Labs is PRPH.

Which industry does the ProPhase Labs company belong to?

The ProPhase Labs industry is Diagnostics & Research.

How many shares does ProPhase Labs have in circulation?

The max supply of ProPhase Labs shares is 4.19M.

What is ProPhase Labs Price to Earnings Ratio (PE Ratio)?

ProPhase Labs PE Ratio is now.

What was ProPhase Labs earnings per share over the trailing 12 months (TTM)?

ProPhase Labs EPS is -19.8 USD over the trailing 12 months.

Which sector does the ProPhase Labs company belong to?

The ProPhase Labs sector is Healthcare.

ProPhase Labs PRPH included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
US Tech Composite IXIC 23613.31 USD
+0.22
3.5B USD 23527.97 USD 23621.72 USD 3.5B USD
US Tech Capital Market Composite RCMP 133.06 USD
+0.23
131.86 USD 133.42 USD
US Tech Composite Total Return XCMP 29035.82 USD
+0.22
28930.89 USD 29046.16 USD
✨New! Portfolio🚀